Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Peumus Boldus Leaf is a clinical-grade allergenic extract used primarily for the diagnosis and treatment of hypersensitivity to the Boldo plant. It belongs to the class of non-standardized plant and food allergenic extracts used in immunotherapy.
Name
Peumus Boldus Leaf
Raw Name
PEUMUS BOLDUS LEAF
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
58
Variant Count
59
Last Verified
February 17, 2026
About Peumus Boldus Leaf
Peumus Boldus Leaf is a clinical-grade allergenic extract used primarily for the diagnosis and treatment of hypersensitivity to the Boldo plant. It belongs to the class of non-standardized plant and food allergenic extracts used in immunotherapy.
Detailed information about Peumus Boldus Leaf
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Peumus Boldus Leaf.
Peumus Boldus Leaf, derived from the evergreen Boldo tree native to the central regions of Chile, is a botanical substance utilized in clinical immunology and allergy medicine. Within the United States Food and Drug Administration (FDA) regulatory framework, Peumus Boldus Leaf is categorized primarily as a Non-Standardized Food Allergenic Extract [EPC] and a Non-Standardized Plant Allergenic Extract [EPC]. While the leaves of the Peumus boldus plant have a long history in traditional South American medicine for digestive and hepatic (liver-related) ailments, its primary clinical application in modern medicine involves the diagnosis and management of IgE-mediated (Immunoglobulin E) allergic reactions.
As a non-standardized extract, the potency of Peumus Boldus Leaf is not measured by a specific biological unit compared to a national reference standard, unlike standardized extracts such as certain grass pollens or insect venoms. Instead, it is prepared through a controlled extraction process designed to capture the allergenic proteins and glycoproteins present in the leaf tissue. Healthcare providers, specifically board-certified allergists and immunologists, utilize these extracts to perform skin prick testing (SPT) or intradermal testing to confirm whether a patient has developed a clinical sensitivity to this specific botanical.
The mechanism of action for Peumus Boldus Leaf depends on its clinical application: diagnostic or therapeutic. At the molecular level, the extract contains specific proteins that act as antigens (substances that trigger an immune response). In a sensitized individual, these antigens cross-link with IgE antibodies already bound to the surface of mast cells and basophils (types of white blood cells involved in allergic reactions). This cross-linking triggers the degranulation of these cells, releasing inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This localized reaction, typically appearing as a 'wheal and flare' (a raised bump and surrounding redness), allows clinicians to diagnose an allergy.
In the context of allergen immunotherapy (allergy shots), Peumus Boldus Leaf works through a process of desensitization. By administering gradually increasing doses of the allergen, the immune system shifts from a Th2-dominated response (which promotes IgE production) to a Th1-dominated or T-regulatory (Treg) response. This shift increases the production of IgG4 (blocking antibodies) and reduces the sensitivity of mast cells, eventually leading to clinical tolerance where the patient no longer reacts severely to environmental or accidental exposure to the leaf.
The pharmacokinetics of allergenic extracts like Peumus Boldus Leaf differ significantly from traditional oral medications because they are typically administered via the epicutaneous (skin surface) or subcutaneous (under the skin) routes.
The FDA-approved indications for Peumus Boldus Leaf extracts include:
Off-label, the leaf extract is sometimes studied for its high concentration of boldine, an alkaloid with potential antioxidant and hepatoprotective properties, though these uses are not currently supported by FDA-approved labeling for the extract form.
Peumus Boldus Leaf is available in the following clinical forms:
> Important: Only your healthcare provider can determine if Peumus Boldus Leaf is right for your specific condition.
Dosage for Peumus Boldus Leaf must be highly individualized based on the patient's sensitivity level and clinical history. There is no 'standard' dose that applies to all patients.
Peumus Boldus Leaf allergenic extracts are generally considered safe for use in children, provided the child is old enough to cooperate with testing and the potential benefits outweigh the risks of a systemic reaction. Dosing follows the same weight-independent escalation protocols used in adults, though clinicians often exercise greater caution with the starting dose in highly sensitive children.
No specific dosage adjustments are required for patients with renal impairment, as the protein load in allergenic extracts is negligible and does not tax renal function.
No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins occurs via systemic proteolysis rather than hepatic enzyme pathways.
Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the primary treatment for a severe reaction) in patients with heart disease must be balanced against the need for immunotherapy.
Peumus Boldus Leaf extracts must only be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.
If a dose in an immunotherapy schedule is missed, the next dose may need to be reduced depending on the length of the delay.
An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level, leading to a systemic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients receiving Peumus Boldus Leaf extracts for testing or therapy will experience localized reactions. These are generally considered a sign that the extract is biologically active.
> Warning: Stop taking Peumus Boldus Leaf and call your doctor immediately if you experience any of these.
Long-term use of Peumus Boldus Leaf in immunotherapy is generally well-tolerated. However, some patients may experience 'Large Local Reactions' (LLR) that increase in frequency over time. There is no evidence that long-term use of allergenic extracts causes autoimmune disease or chronic organ damage. In rare cases, patients may develop a new sensitivity to other components in the extract, though this is clinically uncommon.
While Peumus Boldus Leaf may not have a specific individual black box warning for the 'Boldo' component, all non-standardized allergenic extracts carry a class-wide FDA warning regarding the risk of severe systemic reactions.
FDA Class Warning Summary:
Report any unusual symptoms to your healthcare provider.
Peumus Boldus Leaf extract is intended for use only by physicians specialized in allergy and immunology. Because it is a non-standardized extract, its potency can vary between lots, requiring extreme caution when starting a new vial. Patients must be in a stable state of health before receiving an injection; for example, an active viral infection or an asthma flare-up can lower the threshold for a systemic reaction.
No specific FDA black box warning exists uniquely for Peumus Boldus Leaf, but it is subject to the general requirements for all allergenic extracts. These requirements mandate that the drug be used only in settings where emergency resuscitative equipment and personnel are immediately available. Fatalities have occurred with allergenic extracts when these precautions were not followed.
Peumus Boldus Leaf does not typically cause sedation or cognitive impairment. However, if a patient experiences a systemic reaction or receives antihistamines/epinephrine to treat a reaction, they should not drive or operate machinery until they are fully recovered and cleared by a physician.
There is no direct chemical interaction between alcohol and Peumus Boldus Leaf extract. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption and the severity of a reaction. It is generally advised to avoid alcohol for several hours before and after an injection.
Discontinuing Peumus Boldus Leaf immunotherapy does not require a tapering period. However, the clinical benefits (allergy protection) will gradually diminish over months to years. If therapy is stopped and then resumed after a significant gap, the patient must restart at the lowest concentration to avoid anaphylaxis.
> Important: Discuss all your medical conditions with your healthcare provider before starting Peumus Boldus Leaf.
There are no known direct food interactions with the injectable extract. However, if the patient is using Peumus Boldus as an herbal tea or supplement, they should be aware that the plant contains coumarin, which may have mild anticoagulant (blood-thinning) effects. Consuming large amounts of Boldo tea while on blood thinners like warfarin should be discussed with a doctor.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Peumus Boldus belongs to the Monimiaceae family. While cross-reactivity is not extensively documented, patients allergic to other members of the Laurales order (such as Bay Laurel or Sassafras) should be tested with caution. Furthermore, the extract may contain trace amounts of common plant proteins that could cross-react in patients with broad pollen allergies.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Peumus Boldus Leaf.
FDA Pregnancy Category C. There are no adequate and well-controlled studies of Peumus Boldus Leaf extract in pregnant women.
It is not known whether the allergenic proteins or their metabolites are excreted in human milk. Because these are large proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered very low. The decision to continue immunotherapy while breastfeeding should be based on a risk-benefit analysis by the mother and her physician.
Peumus Boldus Leaf is used in children for both diagnosis and treatment. Clinical trials have shown that immunotherapy can be effective in children as young as 5 years old. The primary challenge in pediatric populations is the child's ability to communicate early symptoms of a systemic reaction (e.g., itchy throat or 'funny feeling'). Dose escalation should be handled with extreme care.
In patients over 65, the prevalence of comorbid conditions (like heart disease or COPD) increases the risk of immunotherapy. Geriatric patients are also more likely to be on medications like beta-blockers or ACE inhibitors, which complicate the management of anaphylaxis. A thorough cardiovascular evaluation is recommended before starting therapy in this age group.
No dosage adjustments are required. The proteins in the extract are not nephrotoxic and are cleared through standard proteolytic pathways.
No adjustments are needed for patients with liver disease. While oral Boldo supplements are sometimes avoided in liver disease due to ascaridole content, the amount of this compound in an allergenic extract injection is toxicologically insignificant.
> Important: Special populations require individualized medical assessment.
Peumus Boldus Leaf extract functions as an exogenous antigen. Upon introduction to the body, the specific proteins (allergens) bind to bivalent IgE antibodies on the surface of mast cells. This triggers a signal transduction cascade involving tyrosine kinases, leading to the release of pre-formed mediators (histamine) and the de novo synthesis of lipid mediators. In immunotherapy, repeated exposure induces T-cell energy and the production of Interleukin-10 (IL-10), which promotes the production of IgG4. IgG4 acts as a 'blocking antibody,' intercepting the allergen before it can bind to IgE.
| Parameter | Value |
|---|---|
| Bioavailability | Low (Subcutaneous) |
| Protein Binding | N/A (Proteins are antigens) |
| Half-life | Minutes to Hours (Proteins) |
| Tmax | 1-2 hours (Systemic absorption) |
| Metabolism | Proteolysis (Non-CYP) |
| Excretion | Renal (as amino acids/peptides) |
The extract is a complex mixture of proteins, glycoproteins, and alkaloids. The primary alkaloid of interest in the plant is Boldine (C19H21NO4), with a molecular weight of 327.37 g/mol. Boldine is poorly soluble in water but soluble in organic solvents. In the allergenic extract, the proteins (typically ranging from 10 to 70 kDa) are the active components for the immune response.
Peumus Boldus Leaf is classified as a Non-Standardized Plant Allergenic Extract. It shares this class with other botanical extracts like Oak, Ragweed (non-standardized), and various food extracts. It is distinct from 'Standardized Extracts' which have a defined Bioequivalent Allergy Unit (BAU) or Protein Nitrogen Unit (PNU) compared to a reference standard.
Common questions about Peumus Boldus Leaf
Peumus Boldus Leaf is primarily used in clinical settings as an allergenic extract for the diagnosis and treatment of allergies to the Boldo plant. In diagnostic testing, a small amount is applied to the skin to see if it triggers an allergic reaction, helping doctors confirm a sensitivity. In immunotherapy, also known as allergy shots, it is injected in gradually increasing amounts to help the patient's immune system become less sensitive over time. It is not used as a standard medication for general illnesses but rather as a specialized tool for allergy management. Always consult an allergist to see if this extract is necessary for your specific symptoms.
The most common side effects are localized to the area where the extract was applied or injected. Patients frequently experience redness, itching, and a raised bump known as a wheal, which typically appears within minutes. Some patients may also develop swelling that appears several hours later and lasts for a day or two. These local reactions are usually mild and can be managed with cold compresses or over-the-counter antihistamines if approved by your doctor. While common, these reactions should be monitored to ensure they do not become excessively large or lead to systemic symptoms.
It is generally recommended to avoid alcohol consumption on the days you receive Peumus Boldus Leaf injections. Alcohol can cause your blood vessels to dilate, which might increase the speed at which the allergen is absorbed into your bloodstream, potentially increasing the risk of a systemic reaction. Additionally, alcohol can mask the early symptoms of an allergic reaction or make them more difficult to treat. While there is no direct chemical interaction, safety is the priority during immunotherapy. Discuss your lifestyle and any alcohol use with your healthcare provider before starting treatment.
Peumus Boldus Leaf is classified as Pregnancy Category C, meaning its safety has not been fully established in pregnant women. The main concern is not the drug itself, but the risk of a severe allergic reaction (anaphylaxis), which could deprive the fetus of oxygen. Most doctors will not start new allergy shots during pregnancy for this reason. However, if you are already on a stable maintenance dose, your doctor may choose to continue the treatment without increasing the dose. Always inform your allergist immediately if you become pregnant while receiving these injections.
When used for diagnostic skin testing, Peumus Boldus Leaf works very quickly, usually producing a result within 15 to 20 minutes. For immunotherapy, however, the process is much slower and requires patience. Most patients do not see a significant reduction in their allergy symptoms until they reach their maintenance dose, which typically takes 3 to 6 months of weekly injections. Full effectiveness and long-term protection usually require continuing the shots for 3 to 5 years. Your doctor will monitor your progress to determine if the treatment is working effectively for you.
Yes, you can stop receiving Peumus Boldus Leaf injections suddenly without experiencing withdrawal symptoms, as it is not a physically addictive substance. However, stopping the treatment before the recommended 3-to-5-year course is finished may result in your allergy symptoms returning. If you miss several doses and then decide to restart, you cannot simply take your last dose; you must start at a much lower dose for safety. It is best to discuss your reasons for wanting to stop with your allergist to plan the best course of action for your allergy management.
If you miss a dose of your Peumus Boldus Leaf immunotherapy, contact your allergist's office to reschedule as soon as possible. The safety of the next dose depends on how much time has passed since your last injection. If only a few days have passed, you may be able to continue with your scheduled dose. If several weeks have passed, your doctor will likely need to reduce the dose to prevent a reaction. Never try to 'double up' on doses to make up for a missed one, as this significantly increases the risk of anaphylaxis.
There is no clinical evidence to suggest that Peumus Boldus Leaf allergenic extracts cause weight gain. The extract consists of proteins and a small amount of glycerin or saline, which do not have the metabolic or hormonal effects associated with weight changes. If you experience weight gain while on immunotherapy, it is likely due to other factors, such as other medications (like oral steroids) or lifestyle changes. If you are concerned about weight changes, discuss them with your primary care physician to identify the underlying cause.
Peumus Boldus Leaf can interact with several types of medications, particularly those used for heart conditions or depression. Beta-blockers are a major concern because they can make it difficult to treat a severe allergic reaction if one occurs. Antihistamines and some antidepressants can interfere with skin testing results by masking the body's natural allergic response. It is vital to provide your allergist with a complete list of all medications, including eye drops and supplements, before starting testing or therapy. Your doctor will determine if any adjustments are needed for your safety.
Peumus Boldus Leaf is a biological product rather than a synthetic drug, so the term 'generic' does not apply in the traditional sense. However, it is produced by several different specialized laboratories that manufacture allergenic extracts. While the extracts from different manufacturers are similar, they are not considered identical or interchangeable. If your doctor switches you to an extract from a different manufacturer, they will typically reduce your dose initially to ensure your safety. This is because the potency of non-standardized extracts can vary between different producers and even between different batches.